Brokerages predict that OPKO Health, Inc. (NASDAQ:OPK – Get Rating) will announce earnings per share (EPS) of ($0.08) for the current quarter, according to Zacks. Two analysts have issued estimates for OPKO Health’s earnings, with the lowest EPS estimate coming in at ($0.11) and the highest estimate coming in at ($0.04). OPKO Health posted earnings per share of $0.05 in the same quarter last year, which would suggest a negative year over year growth rate of 260%. The business is scheduled to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that OPKO Health will report full-year earnings of ($0.09) per share for the current financial year, with EPS estimates ranging from ($0.22) to $0.03. For the next year, analysts expect that the business will report earnings of $0.03 per share, with EPS estimates ranging from ($0.07) to $0.10. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover OPKO Health.
OPKO Health (NASDAQ:OPK – Get Rating) last announced its quarterly earnings results on Thursday, February 24th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.08). The firm had revenue of $401.30 million for the quarter, compared to analyst estimates of $317.26 million. OPKO Health had a negative net margin of 1.70% and a negative return on equity of 1.75%. The company’s revenue was down 18.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.05 EPS.
OPK has been the topic of a number of recent analyst reports. TheStreet cut shares of OPKO Health from a “c” rating to a “d+” rating in a research report on Friday, February 25th. Barrington Research cut shares of OPKO Health from an “outperform” rating to a “market perform” rating in a research report on Monday, January 24th. StockNews.com initiated coverage on shares of OPKO Health in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. Zacks Investment Research cut shares of OPKO Health from a “buy” rating to a “hold” rating and set a $6.00 target price on the stock. in a research report on Monday, January 24th. Finally, Piper Sandler upped their target price on shares of OPKO Health from $5.00 to $6.00 in a research report on Tuesday, January 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, OPKO Health currently has a consensus rating of “Hold” and a consensus target price of $6.25.
In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 100,000 shares of the business’s stock in a transaction on Monday, February 14th. The shares were bought at an average cost of $3.04 per share, for a total transaction of $304,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 1,235,000 shares of company stock worth $3,806,400 over the last quarter. Insiders own 41.47% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Cornerstone Investment Partners LLC purchased a new stake in shares of OPKO Health during the fourth quarter worth approximately $267,000. Kestra Advisory Services LLC increased its stake in shares of OPKO Health by 37.4% during the fourth quarter. Kestra Advisory Services LLC now owns 41,336 shares of the biotechnology company’s stock worth $199,000 after buying an additional 11,260 shares during the period. Castle Rock Wealth Management LLC purchased a new stake in shares of OPKO Health during the fourth quarter worth approximately $73,000. Metropolitan Life Insurance Co NY increased its stake in shares of OPKO Health by 9.9% during the third quarter. Metropolitan Life Insurance Co NY now owns 107,781 shares of the biotechnology company’s stock worth $393,000 after buying an additional 9,693 shares during the period. Finally, Rafferty Asset Management LLC increased its stake in shares of OPKO Health by 24.2% during the third quarter. Rafferty Asset Management LLC now owns 870,666 shares of the biotechnology company’s stock worth $3,178,000 after buying an additional 169,452 shares during the period. Hedge funds and other institutional investors own 26.34% of the company’s stock.
Shares of OPK stock opened at $2.77 on Thursday. The company’s 50-day moving average price is $3.30 and its 200-day moving average price is $3.74. The company has a current ratio of 2.49, a quick ratio of 2.23 and a debt-to-equity ratio of 0.11. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of -55.39 and a beta of 1.86. OPKO Health has a twelve month low of $2.76 and a twelve month high of $5.25.
OPKO Health Company Profile (Get Rating)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
Featured Stories
Get a free copy of the Zacks research report on OPKO Health (OPK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OPKO Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for OPKO Health and related companies with MarketBeat.com’s FREE daily email newsletter.
